Liquid biopsy may make cancer diagnosis easier

A microfluidic chip captures elusive circulating tumor cells from blood—and can support the cells’ growth for further analysis.

The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers, give more accurate prognoses, and test treatment options on cultured cells without subjecting patients to traditional biopsies.

To test the device, researchers ran one-milliliter samples of blood through the chip’s thin chamber. Even when they had added just 3-5 cancer cells to the 5-10 billion blood cells, the chip was able to capture all of the cells in the sample half the time, with an average of 73 percent over 10 trials.

“That’s the highest anybody has shown in the literature for spiking such a low number of cells,” says study leader Sunitha Nagrath, an assistant professor of chemical engineering at University of Michigan.

“If we can get these technologies to work, it will advance new cancer drugs and revolutionize the treatment of cancer patients,” says Max Wicha, professor of oncology and director of the Comprehensive Cancer Center and co-author of the paper on the new device in Nature Nanotechnology.

“Circulating tumor cells will play a significant role in the early diagnosis of cancer and to help us understand if treatments are working in our cancer patients by serving as a ‘liquid’ biopsy to assess treatment responses in real time,” says co-author Diane Simeone, professor of surgery and director of the Translational Oncology Program.

“Studies of circulating tumor cells will also help us understand the basic biologic mechanisms by which cancer cells metastasize or spread to distant organs—the major cause of death in cancer patients.”

Yet these cells aren’t living up to their promise in medicine because they are so difficult to separate from a blood sample, the researchers say. In the blood of early-stage cancer patients, they account for less than one in every billion cells, so catching them is tougher than finding the proverbial needle in a haystack.

“I can burn the haystack or use a huge magnet,” says Nagrath. “When it comes to circulating tumor cells, they almost look like—feel like—any other blood cell.”

Graphene’s ‘nano-arms’

On their microfluidic chip, Nagrath’s team grew dense forests of molecular chains, each equipped with an antibody to grab onto cancer cells.

Even after the cells are caught, it’s still hard to run a robust analysis on just a handful of them, the researchers say. That’s why this demonstration of highly sensitive tumor cell capture, combined with the ability to grow the cells in the same device, is so promising.

Hyeun Joong Yoon, a postdoctoral researcher in the Nagrath lab with a background in electrical engineering, was instrumental in making the microfluidic chip. He started with a silicon base and added a grid of nearly 60,000 flat gold shapes, like four-petaled flowers, each no wider than a strand of hair.

The gold flowers naturally attracted a relatively new material called graphene oxide. These sheets of carbon and oxygen, just a few atoms thick, layered themselves over the gold. This layered formation allowed the team to grow the tumor-cell-catching molecular chains so densely.

“It’s almost like each graphene has many nano-arms to capture cells,” Nagrath says.

Fluorescent tags

The team counted the captured cancer cells by tagging them with fluorescent molecules and viewing them through a microscope. These tags made the cancer cells easy to distinguish from accidentally caught blood cells. They also grew breast cancer cells over six days, using an electron microscope to see how they spread across the gold flowers.

“When you have individual cells, the amount of material in each cell is often so small that it’s hard to develop molecular assays,” Wicha says. “This device allows the cells to be grown into larger quantities so you can do a genetic analysis more easily.”

The chip could capture pancreatic, breast, and lung cancer cells from patient samples. Nagrath was surprised that the device was able to catch about four tumor cells per milliliter of blood from the lung cancer patients, even though they had the early-stage form of the disease.

Nagrath is optimistic that the new technique could reach clinics in three years.

The university is pursuing patent protection for the intellectual property and is seeking commercialization partners to help bring the technology to market.

The National Institutes of Health supported the study.

Source: University of Michigan

chat0 Comments

You are free to share this article under the Creative Commons Attribution-NoDerivs 3.0 Unported license.

0 Comments

We respect your privacy.